Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03294304
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
- NCT03294304 ↗
- Completed
- Masonic Cancer Center, University of Minnesota
- Standard
We haven't built an HCP commentary report on NCT03294304 (nivolumab, cisplatin and 1 more in Muscle Invasive Bladder Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03294304 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 13 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- BLASST-1 (Bladder Cancer Signal Seeking Trial): Phase II Trial of Neoadjuvant Nivolumab With Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Radical Cystectomy
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Nivolumab; Cisplatin; Gemcitabine
- Arms
- Nivolumab, Cisplatin, & Gemcitabine · Experimental
- Enrollment
- 43
- Primary outcomes
- Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging to ≤pT1pN0 Which Includes pT0, pT1, pTa and pTis)
- Sponsor
- Masonic Cancer Center, University of Minnesota with Bristol-Myers Squibb
- Start
- Jan 29, 2018
- Primary completion
- Jun 5, 2020
- Results posted
- Yes
- Registry record
- NCT03294304 · updated Dec 16, 2021